CyBio and Promega have signed a long-term collaboration agreement for the joint development and co-marketing of applications on CyBio's liquid handling instruments
The instrument provider CyBio maintains the co-operation with a partner who develops and distributes worldwide highly specific reagents, kits and assays for gene, protein and cell analysis.
The co-operation's goal is to jointly develop validated application protocols and to market those for high-throughput screening processes in drug development and life science research.
One topic of the collaboration focuses on the automation of Promega's innovative cell-based multiplex-assays.
Such assays deliver increased data quality in toxicity studies of potential drug compounds at lower costs.
Automation of cell-based assays requires extremely gentle dispensing of cell suspensions, a task which CyBio's CyBi-Well and CyBi-Well vario pipettors address in particular by their capability to adapt for optimised pipetting speed.
Robust pipetting heads and CyBio's special technology for secure sealing and exact alignment of pipetting tips allow precise volume dosing in both 384 well and 1536 well microplates.
The successful automation of Promega MultiTox assays with the CyBi-Well pipettor, and its scalability in the 384 and the 1536 high-throughput format, were presented for the first time at the SBS 2007 in Montreal.
Promega's excellent reputation and level of recognition in the scientific community greatly support CyBio in securing a position in the already addressed markets and in opening up new customer segments.
Promega profits in this partnership by CyBio's popular CyBi-Well pipettor, which earned the andsbquo;gold standard' as a result of its precision, reliability and easy handling in high-throughput screening.
The CyBi-Well pipettor and the Promega MultiTox kits provide a robust automation solution which is easily implemented even by users with limited automation experience.
The CyBi-Well pipettor is a compact benchtop instrument to be used standalone or integrated in a complex screening platform.
